SecBot SecBot
8-K ·Filed May 18, 2026

IBRX

ImmunityBio, Inc.
BULLISH
Impact 5/10
Horizonmonths Processed6mo ago SEC0001193125-26-229153
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

Monitor FDA pre-submission meetings and any announced BLA timeline. The agreement strengthens ImmunityBio's BCG supply position, but regulatory approval is not guaranteed. Watch for Data Use Agreement with SWOG/NCI to support BLA.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.76
T+0 close · May 18, 2026 · via day close
Latest settled
−1.42%
T+60 · $7.65
Vs SPY
−7.71%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $7.76entry
  2. T+1 · 6mo ago +3.74%α +2.70% · $8.05
  3. T+5 · 6mo ago +2.26%α +0.01% · $7.94
  4. T+20 · 5mo ago −9.92%α −10.91% · $6.99
  5. T+60 · 3mo ago −1.42%α −7.71% · $7.65
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strain of BCG, securing a second potential source of BCG for bladder cancer treatment. The agreement provides exclusive U.S. rights with no upfront payment, and ImmunityBio will lead regulatory submissions and commercialization. Positive Phase III data from the SWOG S1602 trial supports non-inferiority versus TICE BCG, but the product remains investigational in the U.S.

Key Financial Metrics

Deal Type
partnership

Key Facts

  • Exclusive U.S. development and supply agreement with Japan BCG Laboratory for Tokyo-172 BCG.
  • No upfront or milestone payments; all vials for regulatory submission provided at no cost.
  • ImmunityBio is sole BLA applicant and marketing authorization holder; 10-year term from FDA approval.
  • SWOG S1602 Phase III trial demonstrated non-inferiority of Tokyo-172 BCG vs TICE BCG (HR 0.82, 95.8% CI 0.63-1.08).
  • ImmunityBio now has two potential BCG sources: this agreement and ongoing partnership with Serum Institute of India for rBCG.

Financial Impact

No financial terms disclosed; no upfront payment. Potential future revenue stream if FDA-approved, but magnitude uncertain.

revenue

Risk Factors

  • Tokyo-172 BCG is not FDA-approved; regulatory pathway uncertain.
  • Competition from existing BCG products and other intravesical therapies.
  • Reliance on JBL for manufacturing; supply chain risks.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-229153
Document: d75270dex991.htm0001193125-26-229153
Document: 0001193125-26-229153-index-headers.html0001193125-26-229153
Document: 0001193125-26-229153-index.html0001193125-26-229153
Document: 0001193125-26-229153.txt0001193125-26-229153

US Market Status

Market Closed · Opens Wed (9h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026